Tumor Biology

, Volume 36, Issue 3, pp 1955–1962 | Cite as

Tag SNPs of CFI contributed to the susceptibility for non-small cell lung cancer in Chinese population

  • Yingwen Liu
  • Yanghui Bi
  • Jia Lin
  • Lei Cao
  • Bing He
  • Zhi Zhang
  • Yongping Cui
  • Xuemei Zhang
Research Article


Complement factor I (CFI) plays an important role in the development of non-small cell lung cancer (NSCLC). This study aims to examine the association of CFI genetic variants with the risk of developing NSCLC in Chinese population. A hospital-based case-control study was conducted in 470 patients with NSCLC and 470 controls in Chinese population. Totally, 13 tag single nucleotide polymorphisms (tag SNPs) of CFI were selected by Haploview software using the HapMap database. Genotyping was performed using iPLEX Gold Genotyping Assay and Sequenom MassARRAY. The odds ratios (ORs) and 95 % confidence interval (95 % CI) were calculated by logistic regression model. Our results showed that individuals with rs6822976 GG genotype had a significant decreased risk of NSCLC (OR = 0.64; 95 % CI = 0.42–0.98) when compared with rs6822976 AA genotype carriers. We also found that rs7671905 TT genotype exhibited a significant decreased risk of NSCLC compared with CC genotype with OR (95 % CI) of 0.55 (0.33–0.91). There was no significant association between other selected SNPs and the risk of NSCLC. When stratified by smoking status, the decreased risk of NSCLC was observed to be associated with the genotype with at least one rs6822976 G allele among non-smokers (OR = 0.66; 95 % CI = 0.47–0.93), but not among smokers (OR = 1.01; 95 % CI = 0.67–1.53). For CFI rs7671905 polymorphism, the individuals with at least one T allele have a decreased risk of NSCLC with OR (95 % CI) of 0.71 (0.51–0.99), but not among smokers (OR = 0.93; 95 % CI = 0.61–1.41). When stratified by age, we found that rs7671905 TT genotype has contributed to the decreased risk of NSCLC among older subjects with OR (95 % CI) of 0.46 (0.23–0.95), but not among younger subjects with OR (95 % CI) of 0.64 (0.31–1.34) (P interaction = 0.03). After stratifying by sex, our study showed that rs7671905 TT genotype was related to the risk of NSCLC among males (OR = 0.53; 95 % CI = 0.29–0.98), but not among females (OR = 0.62; 95 % CI = 0.25–1.57) (P interaction = 0.03). CFI genetic variants played an important role in the development of NSCLC in Chinese population.


CFI Tag SNPs NSCLC Genetic variants Single nucleotide polymorphism 



This study was supported by the National Natural Science Foundation of China (81101483 to X. Zhang), Program for New Century Excellent Talents in University (NCET-11-0933 to X. Zhang), Science Fund for Distinguished Young Scholars of Hebei Scientific Committee (2012401022 to X. Zhang), and Leader Talent Cultivation Plan of Innovation Team in Hebei Province (LJRC001 to X. Zhang).

Conflicts of interest



  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.CrossRefPubMedGoogle Scholar
  3. 3.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMedGoogle Scholar
  4. 4.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  5. 5.
    Engels EA, Wu X, Gu J, Dong Q, Liu J, Spitz MR. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res. 2007;67:6520–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Young RP, Hopkins RJ. Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer. 2013;119:1761.CrossRefPubMedGoogle Scholar
  7. 7.
    Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. Mol Cancer Res. 2010;8:1453–65.CrossRefPubMedGoogle Scholar
  8. 8.
    Ostrand-Rosenberg S. Cancer and complement. Nat Biotechnol. 2008;26:1348–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ollert MW, David K, Bredehorst R, Vogel CW. Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b. J Immunol. 1995;155:4955–62.PubMedGoogle Scholar
  10. 10.
    Pangburn MK, Pangburn KL, Koistinen V, Meri S, Sharma AK. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J Immunol. 2000;164:4742–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Lachmann PJ, Muller-Eberhard HJ. The demonstration in human serum of “conglutinogen-activating factor” and its effect on the third component of complement. J Immunol. 1968;100:691–8.PubMedGoogle Scholar
  12. 12.
    Zhou W. The new face of anaphylatoxins in immune regulation. Immunobiology. 2012;217:225–34.CrossRefPubMedGoogle Scholar
  13. 13.
    Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Pio R, Corrales L, Lambris JD. The role of complement in tumor growth. Adv Exp Med Biol. 2014;772:229–62.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Yu X, Rao J, Lin J, Zhang Z, Cao L, Zhang X. Tag SNPs in complement receptor-1 contribute to the susceptibility to non-small cell lung cancer. Mol Cancer. 2014;13:56.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Travis WD, Colby TV, Corri B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumours. 3rd ed. Berlin: Springer; 1999.CrossRefGoogle Scholar
  17. 17.
    Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of ld and haplotype maps. Bioinformatics. 2005;21:263–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2007;25:1265–75.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006;103:2328–33.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171:715–27.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPS) in tumors. Mol Immunol. 2003;40:109–23.CrossRefPubMedGoogle Scholar
  22. 22.
    Yang AC. Long-term care for the elderly in Taiwan. Nurs Sci Q. 2002;15:252–6.PubMedGoogle Scholar
  23. 23.
    Rutkowski MJ, Sughrue ME, Kane AJ, Ahn BJ, Fang S, Parsa AT. The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res. 2010;59:897–905.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tsiftsoglou SA, Willis AC, Li P, Chen X, Mitchell DA, Rao Z, et al. The catalytically active serine protease domain of human complement factor I. Biochemistry. 2005;44:6239–49.CrossRefPubMedGoogle Scholar
  25. 25.
    Jozsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol. 2008;29:380–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Okroj M, Hsu YF, Ajona D, Pio R, Blom AM. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol. 2008;45:169–79.CrossRefPubMedGoogle Scholar
  27. 27.
    Gauba V, Grunewald J, Gorney V, Deaton LM, Kang M, Bursulaya B, et al. Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids. Proc Natl Acad Sci U S A. 2011;108:12821–6.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kondo N, Bessho H, Honda S, Negi A. Additional evidence to support the role of a common variant near the complement factor I gene in susceptibility to age-related macular degeneration. Eur J Hum Genet. 2010;18:634–5.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cipriani V, Matharu BK, Khan JC, Shahid H, Hayward C, Wright AF, et al. No evidence of association between complement factor I genetic variant rs10033900 and age-related macular degeneration. Eur J Hum Genet. 2012;20:1–2. author reply 3.CrossRefPubMedGoogle Scholar
  30. 30.
    Ennis S, Gibson J, Cree AJ, Collins A, Lotery AJ. Support for the involvement of complement factor I in age-related macular degeneration. Eur J Hum Genet. 2010;18:15–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Kew RR, Ghebrehiwet B, Janoff A. Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement. J Clin Invest. 1985;75:1000–7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Boeckler P, Milea M, Meyer A, Uring-Lambert B, Heid E, Hauptmann G, et al. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men: a focus on combined C2/C4 deficiency. Br J Dermatol. 2005;152:265–70.CrossRefPubMedGoogle Scholar
  33. 33.
    Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10:125–31.PubMedGoogle Scholar
  34. 34.
    Radzikowska E, Roszkowski K, Glaz P. Lung cancer in patients under 50 years old. Lung Cancer. 2001;33:203–11.CrossRefPubMedGoogle Scholar
  35. 35.
    Bromen K, Pohlabeln H, Jahn I, Ahrens W, Jockel KH. Aggregation of lung cancer in families: results from a population-based case–control study in Germany. Am J Epidemiol. 2000;152:497–505.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yingwen Liu
    • 1
    • 2
  • Yanghui Bi
    • 3
  • Jia Lin
    • 1
  • Lei Cao
    • 1
  • Bing He
    • 1
  • Zhi Zhang
    • 4
  • Yongping Cui
    • 3
  • Xuemei Zhang
    • 1
  1. 1.Department of Molecular Genetics, College of Life ScienceHebei United UniversityTangshanChina
  2. 2.Department of Epidemiology, College of Life ScienceHebei United UniversityTangshanChina
  3. 3.Key Laboratory of Cellular Physiology, Department of Cell Biology and GeneticsShanxi Medical UniversityTaiyuanChina
  4. 4.Department of Chemotherapy and Radiotherapy of Cancer, Tangshan Gongren HospitalHebei United UniversityTangshanChina

Personalised recommendations